Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...
Boost ROI through strategic CMO alliances, high-density cell culture and automation to improve scalability, vector yields, workflow efficiency and market positioning.Dublin, Oct. 20, 2026 (GLOBE ...
I'm going to begin coverage of Genenta Science (GNTA) with a "Buy" rating and this is based on the stock climbing by 90% on Friday on the back of news that it had partnered its off-the-shelf ...
Fuse Vectors recently announced $5.2 million in pre-seed financing led by HCVC to transform gene therapy development with its cell-free viral vector technology. This funding will accelerate the ...
Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...
Introgen Therapeutic’s (Austin, TX) p53-based INGN 225 cancer vaccine yielded promising safety and efficacy results in a Phase II trial in advanced small cell lung cancer. The personalized therapeutic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results